Evaluation of Safety and Efficacy of Romiplostim in the Treatment of Pediatric Immune Thrombocytopenia: A Real-World Observational Study
{{output}}
Romiplostim, a thrombopoietin receptor agonist, is a second-line therapy for primary immune thrombocytopenia (ITP). This real-world observational study evaluated romiplostim safety and efficacy in 52 children with persistent/chronic ITP. Baseline and follow-up... ...
